Histotripsy, a groundbreaking non-invasive therapy, has gained significant momentum following its FDA clearance. Pivotal clinical trials revealed its exceptional safety and efficacy in treating primary and metastatic liver tumors.
The #HOPE4LIVER trials, conducted internationally in multiple centers, assessed the performance of histotripsy against established benchmarks. In a cohort of 44 patients with 49 targeted tumors, histotripsy successfully ablated the tumors in 95.5% of cases within 36 hours post-procedure.
Experts commend histotripsy’s diverse applications and ease of learning, enabling liver surgeons to effectively treat both primary and metastatic tumors. Notably, the procedure achieved its safety endpoint with only a 6.8% incidence of major complications within 30 days post-treatment.
The successful trial results led to FDA clearance for the non-invasive destruction of liver tumors using histotripsy. This breakthrough offers hope to patients who have not responded to or are intolerant of traditional ablative therapies.
Key findings from the trial include the high technical success rate, favorable safety profile, and the potential to treat complex liver tumors. These findings have sparked excitement among healthcare providers, who recognize histotripsy as a valuable addition to the armamentarium of liver tumor treatments.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
